SPC
CGTX icon

Sigma Planning Corp’s Cognition Therapeutics CGTX Stock Holding History

Sigma Planning Corp’s Portfolio CGTX Stock Details CGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$417K Buy
362,265
+24,500
+7% +$29K 0.01% 1001
2026
Q1 		$257K Buy
337,765
+121,600
+56% +$142K 0.01% 1111
2025
Q4 		$295K Buy
216,165
+89,075
+70% +$145K 0.01% 1039
2025
Q3 		$172K Sell
127,090
-20,900
-14% -$28.5K ﹤0.01% 1233
2025
Q2 		$45.8K Sell
147,990
-460,400
-76% -$155K ﹤0.01% 1232
2025
Q1 		$256K Sell
608,390
-6,100
-1% -$3.58K 0.01% 1028
2024
Q4 		$431K Buy
614,490
+417,300
+212% +$206K 0.01% 790
2024
Q3 		$92.4K Buy
197,190
+25,050
+15% +$25.8K ﹤0.01% 1175
2024
Q2 		$286K Buy
172,140
+12,700
+8% +$25.3K 0.01% 946
2024
Q1 		$290K Buy
159,440
+130,890
+458% +$270K 0.01% 974
2023
Q4 		$52.8K Buy
+28,550
New +$37.8K ﹤0.01% 825

Other funds holding CGTX

BCM
BIOS Capital Management Fort Worth, Texas $41.7M AUM 34.92% 1-Year Est. Return
DC
Davenport & Co Richmond, Virginia $20.4B AUM 18.11% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
C
Chescapmanager Baltimore, Maryland $1.17B AUM 42.44% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
HCM
Hilton Capital Management Garden City, New York $1.47B AUM 18.73% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
CM
CM Management Gulf Breeze, Florida $157M AUM 60.08% 1-Year Est. Return

Sigma Planning Corp's CGTX Position: Q2 2026 in Review

Sigma Planning Corp increased its Cognition Therapeutics (CGTX) stake by 7.3% in Q2 2026, buying an estimated $29K and bringing the position to 362,265 shares worth $417K. The position accounts for 0.01% of the portfolio, ranked #1001.

Sigma Planning Corp first reported a position in CGTX in Q4 2023 and has held it in 11 quarters since. The position peaked at $431K in Q4 2024. 66 funds tracked by Wall St. Rank hold CGTX as of Q2 2026.

  • Sigma Planning Corp held 362,265 shares of Cognition Therapeutics worth $417K as of Q2 2026.
  • Sigma Planning Corp bought 24,500 Cognition Therapeutics shares in Q2 2026, an estimated $29K.
  • Cognition Therapeutics made up 0.01% of Sigma Planning Corp's portfolio in Q2 2026, its #1001 holding.
  • Sigma Planning Corp first reported a position in Cognition Therapeutics in Q4 2023 and has held it in 11 quarters since.
  • Sigma Planning Corp's Cognition Therapeutics position peaked at $431K in Q4 2024.
  • 66 funds tracked by Wall St. Rank held Cognition Therapeutics as of Q2 2026.

Based on Sigma Planning Corp's 13F filing for Q2 2026, filed 7 Aug 2026.